Source - RNS
RNS Number : 6000M
BTG PLC
14 October 2016
 

BTG plc: Notice of Results

 

London, UK, 14 October 2016: BTG plc (LSE: BTG), the specialist healthcare company, announces that it will be releasing its unaudited interim results for the six months ended 30 September 2016 (the "Interim Results") on Thursday 15 November 2016.

 

 

For further information contact:

 

BTG

FTI Consulting



Andy Burrows, VP Corporate & Investor Relations

Mo Noonan / Hanna Skeppner

+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

+44 (0)20 3727 1000



Stuart Hunt, Investor Relations Manager


+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536




Chris Sampson, Corporate Communications Director


+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178


 

About BTG

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: www.btgplc.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORLLFSLIRLSLIR

Related Charts

BTG (BTG)

0.00p (0.00%)
delayed 18:15PM